Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2025 10:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower...
June 03, 2025 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
May 14, 2025 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
May 12, 2025 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
March 01, 2025 12:45 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
February 28, 2025 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
February 27, 2025 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
February 25, 2025 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at Upcoming March Investor Conferences

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
February 10, 2025 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
February 04, 2025 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...